Kyverna Therapeutics, Inc. Common Stock Total Liabilities
Kyverna Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Kyverna Therapeutics, Inc. Common Stock (KYTX) has total liabilities worth $61.44 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check KYTX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Total liabilities of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. This chart illustrates how Kyverna Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Kyverna Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Kyverna Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Kaiwen Education Technology Co Ltd
SHE:002659
|
China | CN¥747.29 Million |
|
Magna Mining Inc
V:NICU
|
Canada | CA$94.67 Million |
|
Seanergy Maritime Holdings Corp
NASDAQ:SHIP
|
USA | $330.35 Million |
|
Barings Corporate Investors
NYSE:MCI
|
USA | $89.92 Million |
|
Jinhong Fashion Group Co Ltd
SHG:603518
|
China | CN¥1.87 Billion |
|
Guangzhou Jinzhong Auto Parts Manufacturing Co. Ltd.
SHE:301133
|
China | CN¥967.46 Million |
|
Talgo SA
MC:TLGO
|
Spain | €1.39 Billion |
|
Energiekontor AG
F:EKT
|
Germany | €926.22 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Kyverna Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see KYTX total asset value.
Liquidity & Leverage Metrics
Kyverna Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Kyverna Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kyverna Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $61.55 Million | +61.73% |
| 2024-12-31 | $38.06 Million | +46.28% |
| 2023-12-31 | $26.02 Million | +28.50% |
| 2022-12-31 | $20.25 Million | -84.63% |
| 2021-12-31 | $131.74 Million | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product ca… Read more